Equity Details
Price & Market Data
Price: $0.786
Daily Change: -$0.005 / 0.64%
Daily Range: $0.77 - $0.80
Market Cap: $19,455,654
Daily Volume: 50,442
Performance Metrics
1 Week: -8.22%
1 Month: 3.32%
3 Months: 4.28%
6 Months: 13.06%
1 Year: -10.33%
YTD: -39.53%
About Pasithea Therapeutics Corp. (KTTA)
Quick market take on Pasithea Therapeutics Corp. (KTTA). Current price: 0.786, daily change: -$0.005 / 0.64%. Market cap: 19,455,654. Performance over 1-week and 1-month.
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.